Titan Stock Story

TTNP -  USA Stock  

USD 2.30  0.06  2.68%

As many baby boomers are still indifferent towards healthcare space, it makes sense to recap Titan Pharma. We will evaluate why we are still confident in anticipation of a recovery. Is the firm current valuation justified? We will cover Titan Pharma valuation to give you a better outlook on taking a position in the stock.
Published over three months ago
View all stories for Titan Pharma | View All Stories
Our prognosis on Titan Pharma (NASDAQ:TTNP) to bounce back in May
This firm currently holds 809 K in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest Titan Pharma is not taking enough advantage from borrowing.
The entity has a beta of 0.8123, which indicates possible diversification benefits within a given portfolio. Let's try to break down what Titan's beta means in this case. As returns on the market increase, Titan Pharma returns are expected to increase less than the market. However, during the bear market, the loss on holding Titan Pharma will be expected to be smaller as well. Even though it is essential to pay attention to Titan Pharma current price movements, it is always good to be careful when utilizing equity historical returns. Our philosophy towards measuring any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Titan Pharma exposes twenty-seven different technical indicators, which can help you to evaluate its performance. Titan Pharma has an expected return of -0.3%. Please be advised to validate Titan Pharma sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change to decide if Titan Pharma stock performance from the past will be repeated at some point in the near future.
We determine the current worth of Titan Pharma using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Titan Pharma based exclusively on its fundamental and basic technical indicators. By analyzing Titan Pharma's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Titan Pharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Titan Pharma. We calculate exposure to Titan Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Titan Pharma's related companies.

Titan Pharma Investment Alerts

Titan investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Titan Pharma performance across your portfolios.Please check all investment alerts for Titan

Titan Pharma Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Titan value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Titan Pharma competition to find correlations between indicators driving the intrinsic value of Titan.

How Titan utilizes its cash?

To perform a cash flow analysis of Titan Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Titan Pharma is receiving and how much cash it distributes out in a given period. The Titan Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Titan Pharma Net Cash Flow from Operations is very stable at the moment as compared to the past year. Titan Pharma reported last year Net Cash Flow from Operations of 5.66 Million

Breaking it down a bit more

The company reported the previous year's revenue of 4.84 M. Net Loss for the year was (7.41 M) with loss before overhead, payroll, taxes, and interest of (1.55 M).

Margins Breakdown

Titan profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Titan Pharma itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Titan Pharma profit margins.
33.1
Profit Margin
27.99
Operating Margin
Operating Margin27.99
EBITDA Margin35.29
Gross Margin0.89
Profit Margin33.1


Titan Pharma Revenue Per Employee is increasing over the last 8 years. The recent value of Titan Pharma Revenue Per Employee is 981,849. Further, Titan Pharma Average Assets is very stable at the moment.

Can Titan Pharma correct the recent decline?

Recent maximum drawdown is at 25.27. Titan Pharma exhibits very low volatility with skewness of 0.39 and kurtosis of 0.13. However, we advise investors to further study Titan Pharma technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Titan Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Titan Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Bottom Line On Titan Pharma

Although some other companies in the biotechnology industry are either recovering or due for a correction, Titan may not be as strong as the others in terms of longer-term growth potentials. The bottom line, as of the 12th of April 2021, we believe that at this point, Titan Pharma is undervalued with significantly high odds of financial turmoil within the next 2 years. Our ongoing buy-hold-sell recommendation on the firm is Cautious Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Titan Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com